RARE

Ultragenyx Pharmaceutical Inc

16.10

Oct 30 • 3:59 PM ET -0.68 (-4.05%)

16.10

Aftermarket • 7:30 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

Peers: BMRN PTCT IONS MIRM MREO ASND SRPT RYTM QURE KRYS

| Held by: XBI VTI IWM VB VBK VXF IBB SCHA VTWO IWN

Scroll to Statements

Index	RUT
Market Cap	1.59B
Enterprise Value	2.50B
Income	-586.41M
Sales	716.93M
Book/sh	-2.96
Cash/sh	3.05
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	1371
IPO	Jan 31, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	2.21
P/B	-
P/C	5.27
P/FCF	-
EV/EBITDA	-
EV/Sales	3.48
Quick Ratio	1.56
Current Ratio	1.73
Debt/Eq	-
LT Debt/Eq	-
Option/Short	Yes / Yes

EPS (ttm)	-5.84
EPS next Y	-0.65
EPS next Q	-1.10
EPS this Y	21.10%
EPS next Y	85.93%
EPS next 5Y	-
EPS past 3/5Y	16.78% -13.72%
Sales past 3/5Y	22.81% 19.95%
EPS Y/Y TTM	-5.66%
Sales Y/Y TTM	17.50%
EPS Q/Q	22.67%
Sales Q/Q	28.53%
Earnings	Nov 03 AMC
EPS/Sales Surpr.	26.08% 16.89%

Insider Own	8.51%
Insider Trans	-0.46%
Inst Own	113.72%
Inst Trans	3.70%
ROA	-45.63%
ROE	-656.54%
ROIC	-70.23%
Gross Margin	78.47%
Oper. Margin	-73.77%
Profit Margin	-81.79%
SMA20	3.55%
SMA50	-5.36%
SMA200	-29.68%
Trades

Shs Outstand	98.30M
Shs Float	90.19M
Short Float	22.34%
Short Ratio	4.82
Short Interest	20.15M
52W High	39.89 -59.64%
52W Low	12.73 26.47%
Volatility	5.60% 4.96%
ATR (14)	0.85
RSI (14)	49.82
Beta	0.38
Rel Volume	0.56
Avg Volume	4.18M
Volume	2,333,276

Perf Week	2.88%
Perf Month	9.15%
Perf Quarter	-35.65%
Perf Half Y	-35.00%
Perf YTD	-30.00%
Perf Year	-54.22%
Perf 3Y	-51.33%
Perf 5Y	-80.82%
Perf 10Y	-74.29%
Recom	2.05
Target Price	26.25
Prev Close	16.78
Price	16.10
Change %	-4.05%

Consensus

Buy

Avg. Price Target

$26.25

Implied Upside

+63.0%

Analysts13incl. previous ratings

Rating Distribution5 Buy · 8 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 15, 2026	Initiated	UUBS	Neutral	$16	-0.6%
Sep 03, 2026	Downgrade	WWilliam Blair	Outperform → Mkt Perform
Sep 03, 2026	Downgrade	WWells Fargo	Overweight → Equal Weight	$18	+11.8%
Sep 03, 2026	Downgrade	RRobert W. Baird	Outperform → Neutral	$16	-0.6%
Sep 03, 2026	Downgrade	JJP Morgan	Overweight → Neutral	$36	+123.6%
Sep 03, 2026	Downgrade	EEvercore ISI	Outperform → In-line	$16	-0.6%
Sep 03, 2026	Downgrade	BBofA Securities	Buy → Neutral
Mar 24, 2026	Downgrade	GGoldman	Buy → Neutral	$25	+55.3%
Oct 20, 2025	Initiated	WWells Fargo	Overweight	$65	+303.7%
Jul 28, 2025	Resumed	HH.C. Wainwright	Buy	$80	+396.9%
May 28, 2025	Initiated	WWilliam Blair	Outperform
Jun 06, 2024	Upgrade	GGoldman	Neutral → Buy	$56 → $67	+316.1%
Apr 22, 2024	Initiated	RRBC Capital Mkts	Outperform	$77	+378.3%
Dec 08, 2023	Initiated	WWells Fargo	Overweight	$72	+347.2%
Jun 14, 2023	Resumed	CCredit Suisse	Outperform	$96	+496.3%
Jun 06, 2023	Upgrade	EEvercore ISI	In-line → Outperform	$60 → $80	+396.9%
Apr 26, 2023	Initiated	CCantor Fitzgerald	Overweight	$114	+608.1%
Jan 18, 2023	Resumed	CCanaccord Genuity	Buy	$90	+459.0%
Dec 30, 2022	Resumed	HH.C. Wainwright	Buy	$82	+409.3%
Nov 03, 2022	Upgrade	RRobert W. Baird	Neutral → Outperform	$50	+210.6%

Oct-27-26 08:37PM	Ultragenyx Faces A Credibility Test As Catalyst Season Collides With A 43% Selloff (Earnings Whispers)
04:05PM	Ultragenyx to Host Conference Call for Third Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Oct-14-26 08:30AM	Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $203 Million (GlobeNewswire)
Oct-09-26 11:18AM	FDA review docs spark Revolution sell-off; Zealand diabetes data underwhelm analysts (BioPharma Dive)
Oct-07-26 12:00PM	Ultragenyx shares rise after agreeing to sell FDA priority review voucher for $210 million (Proactive)
11:51AM	Loading…
11:51AM	Ultragenyx Lands $210M Deal To Sell FDA Priority Review Voucher Retail Sees Huge Buying Opportunity (Stocktwits)
08:30AM	Ultragenyx Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million (GlobeNewswire)
07:10AM	MARKETS LIVE: Wall Street ends lower as 30-year Treasury yield hits 2002 high (Proactive)
Oct-02-26 02:00AM	Ultragenyx Announces Marketing Authorisation Application (MAA) Submission to the European Medicines Agency (EMA) for the First Investigational Gene Therapy for MPS IIIA (Sanfilippo Syndrome Type A) (GlobeNewswire)
Sep-22-26 03:09PM	RARE Stock Climbs This Week As Investors Look Past Trial Failure To Gene Therapy Launches, Trial Results (Stocktwits) +6.59%
Sep-18-26 08:16AM	Ultragenyx Gets A Much-Needed Win, Says Cantor Sees $400M Opportunity After FDA Approves Neurodegenerative Disease Therapy (Stocktwits)
06:24AM	Ultragenyx prices Sanfilippo gene therapy at $4M; Bristol Myers shelves Orum drug (BioPharma Dive)
Sep-17-26 07:33PM	ABEO Stock Gains On Approval For A Drug Abeona Sold, Rating For The One It Sells (Stocktwits) +12.58%
06:36PM	RARE Stock Jumps 13% Extends Gains After-Hours As FDA Clears First Sanfilippo Gene Therapy (Stocktwits)
03:54PM	Ultragenyx Stock Jumps on Landmark FDA Approval (Barrons.com)
03:48PM	Loading…
03:48PM	Ultragenyx Announces Approval of FAYUVI Gene Therapy, the First-Ever FDA-Approved Treatment for Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Sep-16-26 03:38PM	RARE Stock Hits Fresh 52-Week Low As Sanfilippo Drug Ruling Nears Failed Angelman Syndrome Trial Weighs On Shares (Stocktwits)
Sep-15-26 09:51PM	Biotech Midweek Pulse: XBI Loses Steam After Hot 2026 Run Here Are The Stocks And Catalysts To Watch Next (Stocktwits)
Sep-04-26 03:24AM	RARE Stock Crashes In Worst Day Ever Pharma Bro Martin Shkreli Calls It Very Cheap, Floats BioMarin Buyout (Stocktwits)
12:22AM	Why Did NIO, RARE, MCD Stocks Fall To 52-Week Lows? (Stocktwits)
Sep-03-26 05:19PM	IONS Edges Up After-Hours On FDAs Green Light For Neurology Drug After Being Dragged Down By Ultragenyxs Failed Trial (Stocktwits) -44.03%
05:18PM	Stocks to Watch Thursday Recap: Snowflake, Broadcom, HPE, Ultragenyx (The Wall Street Journal)
10:52AM	Ultragenyx mulls fate of rare disease programme on Phase III flop (Clinical Trials Arena)
10:34AM	Inside Ultragenyx's Drug Flop: High Costs, Downgrades, and a Pipeline Play (Barrons.com)
09:31AM	Broadcom upgraded, Ultragenyx downgraded: Wall Street's top analyst calls (The Fly)
07:46AM	Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet. (Barrons.com)
07:00AM	Ultragenyx Shares Fall After Phase 3 Aspire Study Misses Primary Endpoint (InvestorsHub)
06:50AM	RARE Stock Heads For Record Low: Angelman Trial Miss Leads To Wall Street Downgrades This Analyst Sees Another Problem Ahead (Stocktwits)
05:45AM	Premarket movers: Snowflake, Five Below surge after strong earnings (Investing.com)
Sep-02-26 06:45PM	Why Did RARE Stock Slump 46% After-Hours? (Stocktwits)
04:01PM	Loading…
04:01PM	Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome (GlobeNewswire)
Sep-01-26 04:05PM	Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatment of GENGLYCOS (also known as DTX401) AAV Gene Therapy in GSDIa in The Journal of Inherited Metabolic Disease (GlobeNewswire)
Aug-25-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-20-26 09:45AM	Drone Innovator Duke Robotics Receives $12 Price Target and Buy Rating From Wall Street Analyst (NASDAQ: DUKR) (FinanceWire)
08:48AM	Ultragenyxs Gene-Therapy Win Could Unlock A Long Revenue Tailwind, Says Wells Fargo This Analyst Sees 265% Upside For RARE Stock (Stocktwits)
07:13AM	Ultragenyx, after setbacks, nabs first gene therapy approval (BioPharma Dive)
05:32AM	Strategy stock surges on bitcoin bounce, and other early market movers (MarketWatch)
Aug-19-26 06:55PM	RARE Stock Jumps 6% After-Hours On First Gene Therapy Approval, New Priority Review Voucher (Stocktwits)
05:21PM	Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Aug-18-26 07:44PM	RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy (Stocktwits)
Aug-05-26 01:01AM	Ultragenyx Pharmaceutical Inc (RARE) (Q2 2026) Earnings Call Highlights: Record Revenue and ... (GuruFocus.com)
Aug-04-26 04:55PM	Ultragenyx: Q2 Earnings Snapshot (Associated Press)
04:05PM	Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Aug-03-26 05:26PM	MRNA, LNTH, BMY, CAPR, RARE Stocks In Focus These FDA Decisions Could Shape August Trading (Stocktwits)
Jul-28-26 04:05PM	Ultragenyx to Host Conference Call for Second Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Jul-24-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-08-26 09:08AM	Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact (GlobeNewswire)
Jun-19-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-26 04:30PM	Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire)
May-22-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-06-26 04:30PM	Ultragenyx to Participate at Bank of America's 2026 Healthcare Conference (GlobeNewswire)
May-05-26 04:07PM	Ultragenyx: Q1 Earnings Snapshot (Associated Press)
04:01PM	Ultragenyx Reports First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-29-26 08:00AM	Ultragenyx to Host Conference Call for First Quarter 2026 Financial Results and Corporate Update (GlobeNewswire)
Apr-24-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-02-26 08:30AM	Ultragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) (GlobeNewswire)
Mar-30-26 08:30AM	Ultragenyx Announces FDA Clearance of Investigational New Drug (IND) Application for UX016, a Sialic Acid Prodrug for the Treatment of GNE Myopathy (GlobeNewswire)
03:41AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-24-26 09:36AM	Microsoft reinstated, Ralph Lauren upgraded: Wall Street's top analyst calls (The Fly) -8.73%
Mar-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-13-26 06:17AM	Evotec, Vistagen lay off staff; Immutep shares collapse on study failure (BioPharma Dive)
Mar-12-26 08:30AM	Ultragenyx Announces Positive 36-Week Data from Phase 3 Study of DTX301 AAV8 Gene Therapy for the Treatment of Ornithine Transcarbamylase (OTC) Deficiency (GlobeNewswire)
04:18AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Mar-11-26 09:00AM	LEVI & KORSINSKY, LLP: CEO AND CMO NAMED AS CONTROL PERSON DEFENDANTS IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Mar-04-26 09:00AM	LEVI & KORSINSKY, LLP: RARE STOCK DECLINED OVER 42% FOLLOWING PHASE III STUDY FAILURE DISCLOSURE (PR Newswire)
Feb-25-26 09:00AM	LEVI & KORSINSKY, LLP: MANAGEMENT CONFIDENCE REPRESENTATIONS CHALLENGED IN ULTRAGENYX PHARMACEUTICAL SECURITIES ACTION (PR Newswire)
Feb-24-26 10:19AM	Ultragenyx Pharmaceutical Inc. (RARE): A Bull Case Theory (Insider Monkey)
Feb-23-26 04:30PM	Ultragenyx to Participate at Investor Conferences in March (GlobeNewswire)
08:30AM	Ultragenyx Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application (BLA) for DTX401 AAV Gene Therapy for Glycogen Storage Disease Type Ia (GSDIa) (GlobeNewswire)
Feb-20-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-16-26 12:23PM	Strong Rare Disease Pipeline Drives Favorable Sentiment for Ultragenyx (RARE) (Insider Monkey)
Feb-14-26 01:29AM	Ultragenyx (RARE) Announces Positive Long-Term Clinical Data for UX111 Gene Therapy in Sanfilippo Syndrome Type A (Insider Monkey)
Feb-13-26 01:21PM	Why Is Ultragenyx Stock Sinking Friday? (Benzinga) -12.68%
10:23AM	Ultragenyx Q4 Loss Wider Than Expected, Revenues Increase Y/Y (Zacks)
05:08AM	Ultragenyx cuts jobs as it seeks path to profit in 2027 (BioPharma Dive)
12:02AM	Ultragenyx Pharmaceutical Inc (RARE) Q4 2025 Earnings Call Highlights: Strong Revenue Growth ... (GuruFocus.com)
Feb-12-26 08:14PM	Ultragenyx Pharmaceutical Q4 Earnings Call Highlights (MarketBeat)
06:00PM	Ultragenyx (RARE) Reports Q4 Earnings: What Key Metrics Have to Say (Zacks)
05:15PM	Ultragenyx (RARE) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
04:18PM	Ultragenyx: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Ultragenyx Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Update (GlobeNewswire)
Feb-09-26 03:30AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RARE (PR Newswire)
Feb-07-26 03:33AM	Ultragenyx Pharmaceutical (RARE) Resubmits Biologics License Application for Gene Therapy Treatment (Insider Monkey)
Feb-06-26 07:40AM	Ultragenyx Pharmaceutical Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights RARE (Business Wire)
Feb-05-26 04:05PM	Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2025 Financial Results and Corporate Update (GlobeNewswire)
10:00AM	Ultragenyx (RARE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release (Zacks)
Feb-03-26 12:58PM	Ultragenyx Says Gene Therapy Shows Lasting Benefits, Slows Brain Decline In Fatal Childhood Disorder (Benzinga)
08:00AM	Ultragenyx Announces Positive Longer-Term Data Demonstrating Treatment with UX111 Gene Therapy Results in Sustained, Significant Reductions in CSF-HS and Continued Meaningful Improvements in Clinical Function Across Multiple Developmental Domains in Children with Sanfilippo Syndrome (MPS IIIA) (GlobeNewswire)
Feb-02-26 11:03AM	Ultragenyx Pharmaceutical Resubmits UX111 BLA for Sanfilippo Syndrome (Zacks)
Jan-30-26 08:30AM	Ultragenyx Resubmits Biologics License Application for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA) to U.S. FDA (GlobeNewswire)
Jan-23-26 04:30PM	Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
02:05PM	Ultragenyx Stock Declines After Missing Primary Endpoints on its Phase III Orbit and Cosmic Studies (PR Newswire)
Jan-21-26 04:58PM	Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch (Benzinga)
Jan-12-26 10:11AM	Morgan Stanley Trims Ultragenyx (RARE) PT to $50 While Betting on 2026 Biotech Recovery (Insider Monkey) +8.26%
07:30AM	Ultragenyx Provides Financial and Business Updates at J.P. Morgan Annual Healthcare Conference (GlobeNewswire)
Jan-09-26 03:16AM	Analysts Lower Ultragenyx (RARE) Target but Stay Bullish (Insider Monkey)
Jan-07-26 04:05PM	Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.36%
Jan-05-26 03:56AM	Novo launches Wegovy pill; Argenx to swap CEOs (BioPharma Dive)
Dec-31-25 09:50AM	RARE Rises on Completion of Rolling Submission for AAV Gene Therapy (Zacks)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Horn Howard	Chief Financial Officer	Oct 15 '26	Sale	15.27	7,066	107,898	89,229	Oct 19 01:48 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 15 '26	Sale	13.57	1,283	17,410	67,863	Sep 15 06:57 PM
THEODORE HUIZENGA	Officer	Sep 15 '26	Proposed Sale	13.61	1,283	17,462		Sep 15 04:33 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Sep 03 '26	Sale	13.99	161	2,252	69,146	Sep 08 12:29 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Aug 03 '26	Sale	24.92	1,900	47,348	92,562	Aug 04 03:15 PM
Horn Howard	Chief Financial Officer	Aug 03 '26	Sale	24.92	4,696	117,024	96,295	Aug 04 03:13 PM
HOWARD HORN	Officer	Aug 03 '26	Proposed Sale	24.92	4,696	117,024		Aug 03 04:18 PM
Horn Howard	Chief Financial Officer	Jul 01 '26	Sale	33.13	4,698	155,645	100,991	Jul 06 03:37 PM
HOWARD HORN	Officer	Jul 01 '26	Proposed Sale	33.13	4,698	155,645		Jul 01 04:19 PM
Sanders Corazon (Corsee) D.	Director	Jun 15 '26	Sale	25.05	2,000	50,100	21,095	Jun 15 06:50 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Jun 15 '26	Sale	24.62	1,899	46,753	94,462	Jun 15 06:46 PM
KARAH PARSCHAUER	Officer	Jun 15 '26	Proposed Sale	24.35	3,799	92,506		Jun 15 04:50 PM
CORAZON D. SANDERS	Director	Jun 15 '26	Proposed Sale	25.05	2,000	50,100		Jun 15 04:12 PM
Horn Howard	Chief Financial Officer	Jun 01 '26	Sale	23.77	4,653	110,602	105,689	Jun 01 07:11 PM
HOWARD HORN	Officer	Jun 01 '26	Proposed Sale	23.77	4,653	110,602		Jun 01 04:08 PM
SULIMAN SHEHNAAZ	Director	May 18 '26	Sale	25.12	5,740	144,189	27,951	May 18 06:41 PM
SHEHNAAZ SULIMAN	Director	May 18 '26	Proposed Sale	25.12	5,740	144,189		May 18 04:50 PM
Crombez Eric	EVP and Chief Medical Officer	May 05 '26	Sale	24.96	344	8,586	111,189	May 06 02:51 PM
Horn Howard	Chief Financial Officer	May 01 '26	Sale	24.90	4,683	116,607	110,342	May 04 05:35 PM
HOWARD HORN	Officer	May 01 '26	Proposed Sale	24.90	4,683	116,607		May 01 04:06 PM
Horn Howard	Chief Financial Officer	Apr 01 '26	Sale	20.97	4,683	98,203	80,351	Apr 02 06:19 PM
HOWARD HORN	Officer	Apr 01 '26	Proposed Sale	20.97	4,683	98,203		Apr 01 04:12 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 06 '26	Sale	21.40	6,018	128,785	70,328	Mar 10 04:51 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 10 '26	Sale	22.67	3,508	79,526	66,820	Mar 10 04:51 PM
KARAH PARSCHAUER	Officer	Mar 10 '26	Proposed Sale	22.67	3,508	79,526		Mar 10 04:42 PM
KARAH PARSCHAUER	Officer	Mar 06 '26	Proposed Sale	21.40	6,018	128,775		Mar 06 05:28 PM
Pinion John Richard	See Remarks	Mar 02 '26	Sale	22.80	10,029	228,661	110,026	Mar 03 07:09 PM
Harris Erik	EVP & Chief Commercial Officer	Mar 02 '26	Sale	22.80	10,539	240,289	89,515	Mar 03 07:08 PM
KAKKIS EMIL D	President & CEO	Mar 02 '26	Sale	22.80	54,404	1,240,411	658,994	Mar 03 07:06 PM
Parschauer Karah Herdman	EVP and Chief Legal Officer	Mar 02 '26	Sale	22.80	8,135	185,478	76,346	Mar 03 06:51 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Mar 02 '26	Sale	22.80	1,632	37,210	48,670	Mar 03 06:51 PM
Horn Howard	Chief Financial Officer	Mar 02 '26	Sale	22.70	8,409	190,914	86,669	Mar 03 06:50 PM
Horn Howard	Chief Financial Officer	Mar 03 '26	Sale	22.40	1,635	36,624	85,034	Mar 03 06:50 PM
Crombez Eric	EVP and Chief Medical Officer	Mar 02 '26	Sale	22.80	7,029	160,261	76,301	Mar 03 06:49 PM
HOWARD HORN	Officer	Mar 03 '26	Proposed Sale	22.40	1,635	36,624		Mar 03 04:41 PM
HOWARD HORN	Officer	Mar 02 '26	Proposed Sale	22.54	3,119	70,302		Mar 02 05:08 PM
Horn Howard	Chief Financial Officer	Feb 02 '26	Sale	23.56	3,061	72,117	88,935	Feb 03 12:00 PM
HOWARD HORN	Officer	Feb 02 '26	Proposed Sale	23.56	3,061	72,117		Feb 02 04:09 PM
Horn Howard	Chief Financial Officer	Jan 02 '26	Sale	22.84	3,150	71,946	91,996	Jan 05 04:07 PM
HOWARD HORN	Officer	Jan 02 '26	Proposed Sale	22.84	3,150	71,946		Jan 02 04:10 PM
Huizenga Theodore Alan	SVP, Chief Accounting Officer	Dec 29 '25	Sale	34.38	85	2,922	50,450	Dec 30 01:49 PM
Horn Howard	Chief Financial Officer	Dec 10 '25	Sale	36.38	3,081	112,087	95,146	Dec 11 12:10 PM
HOWARD HORN	Officer	Dec 10 '25	Proposed Sale	36.38	3,081	112,087		Dec 10 04:05 PM

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza. The company was founded by Emil D. Kakkis in April 2010 and is headquartered in Novato, CA.

Ph.D.Dr. Emil D. Kakkis M.D.

Executive VP of Corporate Strategy & CFOMr. Howard Horn

Chief Legal Officer & Executive VP of Corporate AffairsMs. Karah Herdman Parschauer J.D.

Executive VP & Chief Commercial OfficerMr. Erik Harris M.B.A.

Chief Medical Officer & Executive VPDr. Eric Crombez M.D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RARE

Ultragenyx Pharmaceutical Inc

Upgrade your Finviz experience